| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C20H20ClN3OS2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
YM-1 is a stable analog of MKT-077 and an orally active Hsp70 inhibitor. It induces cell death of HeLa cells and up-regulates the level of p53 and p21 proteins[1][2]. It is supplied as a brown to reddish brown solid (C20H20ClN3OS2, MW 417.98) at 98.49% purity.
Physical & Chemical Properties
| CAS Number | 409086-68-6 |
|---|---|
| Molecular Formula | C20H20ClN3OS2 |
| Molecular Weight | 417.98 g/mol |
| Purity | 98.49% |
| Appearance | Solid |
| Color | Brown to reddish brown |
| SMILES | CN(C1=CC=CC=C1S/2)C2=C3C(N(CC)/C(S\3)=C/C4=[N+](C)C=CC=C4)=O.[Cl-] |
| Signaling Pathway | Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Immunology/Inflammation |
| Solubility | In Vitro: H2O: 50 mg/mL (119.62 mM; Requires sonication) DMSO: 30 mg/mL (71.77 mM; Requires sonication and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[2]. Khondoker Md Zulfiker Rahman, et al. Effect of an Inhibitor of HSP70, YM-1, on Hikeshi Knockout Cells. Thermal Medicine. 2017, 33(4):129-134.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | 50 mg/mL (119.62 mM) | requires sonication |
| DMSO | 30 mg/mL (71.77 mM) | requires sonication and warming and heat to 60°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (4.98 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (4.98 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
YM-1 enhances the Hsp70-dependent steps of nNOS maturation and partly prevents formation of the ATP-bound form[1]. YM-1 (0-200 μM) stimulates Hsp70 binding to its unfolded substrate[1]. YM-1 (0.001-1000 μM) shifts Hsp70 into its tight-affinity conformation and binds Hsp70 (IC50 value of 8.2 μM)[1]. At 0, 0.1, 0.5 and 1 μM for 24 hours, YM-1 enhances nNOS ubiquitination[1]. In HeLa cells, YM-1 (5 and 10 μM; 24 and 48 hours) induces cell death, and in hTERT-RPE1 cells it causes growth arrest[2]. YM-1 (10 μM; 48 hours) raises p53 and p21 protein levels and lowers FoxM1 and survivin levels[2].
Western Blot Analysis[2]
| Cell Line | HeLa and hTERT-RPE1 cell lines |
|---|---|
| Concentration | 10 μM |
| Incubation Time | 48 hoursI |
| Result | Increased the level of p53 and p21 and decreased the level of FoxM1 and survivin. |
In Vivo
Oral administration of YM-1 (1 mM; 7 days) activates Hsp70 and thereby rescues polyQ toxicity in Drosophila[1].
| Animal Model | UAS-hAR52Q flies with polyQ AR-induced dihydrotestosterone (DHT) phenotype[1] |
|---|---|
| Dosage | 1 mM |
| Administration | Oral administration; 1 mM, for 7 days |
| Result | Weakened the DHT-dependent eye degeneration phenotype and rescued DHT-dependent pupal toxicity of the polyQ AR. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
bioRxiv. 2024 October 06.
